CJC-1295 vs tesamorelin compared: how these growth hormone-releasing peptides differ in half-life, FDA status, fat loss, and muscle growth research.
CJC-1295 and tesamorelin are both growth hormone-releasing hormone (GHRH) analogs, but they are not interchangeable. Tesamorelin is an FDA-approved prescription drug for excess abdominal fat in adults with HIV-associated lipodystrophy, while CJC-1295 is an unapproved research peptide with no approved human indication. The practical differences come down to half-life, regulatory status, and how much human trial data backs each compound.
Quick Answer: How the Two Peptides Differ
- Approval: Tesamorelin is FDA-approved for one specific condition; CJC-1295 has no FDA approval for human use.
- Half-life: CJC-1295 with DAC stays active for days, while tesamorelin clears in minutes and is dosed daily.
- Human data: Tesamorelin has large randomized trials; CJC-1295 has only small, early studies.
- Overlap: Both raise growth hormone and IGF-1, so their side effects and monitoring requirements are similar.
What Is CJC-1295?
CJC-1295 is a synthetic GHRH analog engineered to resist enzymatic breakdown. It exists in two forms that buyers often confuse: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC, also called mod GRF(1-29).
The DAC version binds to albumin in the bloodstream, which stretched its half-life to roughly 6–8 days in early human studies. The no-DAC version stays active for only about 30 minutes, which is why it is usually paired with a growth hormone-releasing peptide such as ipamorelin.
CJC-1295 has never been approved by the FDA for any human use. It is sold online as a "research chemical," meaning purity, sterility, and actual peptide content are not guaranteed.
What Is Tesamorelin?
Tesamorelin is a GHRH analog with a trans-3-hexenoyl group that makes it more stable than natural GHRH. It is sold under brand names including Egrifta and Egrifta SV and is given as a once-daily subcutaneous injection.
The FDA approved tesamorelin to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, a condition involving abnormal fat redistribution. Trials in that population showed measurable reductions in visceral adipose tissue along with higher IGF-1 levels.
Tesamorelin is prescription-only, so a clinician must evaluate and monitor anyone using it. It is not approved for general weight loss or bodybuilding.
CJC-1295 vs Tesamorelin: Side-by-Side Comparison
| Feature | CJC-1295 with DAC | CJC-1295 no DAC | Tesamorelin |
|---|---|---|---|
| Class | GHRH analog | GHRH analog | GHRH analog |
| Half-life | About 6–8 days | About 30 minutes | Minutes; dosed daily |
| FDA status | Not approved | Not approved | Approved for HIV-associated lipodystrophy |
| Human trial data | Very limited | Very limited | Multiple randomized trials |
| Main studied outcome | GH and IGF-1 elevation | GH and IGF-1 elevation | Reduction in visceral abdominal fat |
| Dose studied or labeled | Single doses of 30–90 mcg/kg in early trials | About 100 mcg per research dose | 1.4 mg or 2 mg once daily per labeling |
| Access | Research chemical market | Research chemical market | Prescription only |
| Common side effects | Injection-site reactions, joint pain, fluid retention | Similar, but shorter acting | Injection-site reactions, joint pain, fluid retention, elevated IGF-1 |
The figures above describe published research protocols and FDA labeling. They are not a recommendation to use any of these compounds.
Tesamorelin vs CJC-1295 for Fat Loss
For fat loss, tesamorelin has the stronger evidence base by a wide margin. Its clinical trials measured visceral adipose tissue directly and showed reductions in that specific fat depot in people with HIV-associated lipodystrophy.
CJC-1295 has no comparable body-composition trials. The small early studies focused on safety, GH levels, and IGF-1 rather than on fat mass, so anyone comparing tesamorelin vs cjc-1295 for fat loss is weighing one well-studied drug against a largely unstudied peptide.
Neither compound is a general weight-loss drug. Tesamorelin's approval covers a narrow patient population, and it is not indicated for cosmetic fat reduction in healthy adults.
Tesamorelin vs CJC 1295 for Muscle Growth
Neither peptide is a muscle-building agent in the way anabolic steroids are. Growth hormone and IGF-1 can affect connective tissue and fluid balance, but trials of GH in healthy adults have not produced reliable strength or lean-mass gains.
Tesamorelin trials tracked fat, not muscle hypertrophy. CJC-1295 has essentially no body-composition data in humans. Most people researching tesamorelin vs cjc 1295 for muscle growth are looking at an endpoint neither compound was studied to improve.
Bodybuilders commonly stack a GHRH analog with a GHRP, which is why searches such as tesamorelin vs ipamorelin vs cjc 1295 and cjc-1295 ipamorelin vs tesamorelin are popular. Stacking does not change the fact that human muscle-growth evidence for these peptides is thin.
FDA Status, Legality, and Sourcing Risks
Tesamorelin is legal in the United States only with a prescription, and it is dispensed through specialty pharmacies. CJC-1295 cannot legally be sold as a dietary supplement or an approved drug for human use; it is typically marketed as a "not for human consumption" research chemical.
That distinction matters for quality. Independent testing has repeatedly found that research peptides can be underdosed, mislabeled, or contaminated.
Both compounds raise IGF-1, and sustained IGF-1 elevation is associated with fluid retention, joint pain, and carpal tunnel symptoms. Tesamorelin's label warns against use in people with active malignancy. Anyone considering either peptide should discuss it with a healthcare professional instead of self-dosing.
Online discussions of tesamorelin vs cjc-1295 often blend personal anecdotes with lab data, and anecdotes are not evidence of safety or effectiveness.
Related Comparisons People Search For
Most people searching cjc-1295 with dac vs tesamorelin are really choosing between a long-acting research peptide and a short-acting prescription drug. Other frequent comparisons include tesamorelin vs sermorelin vs cjc-1295, where sermorelin is the shortest-acting GHRH analog of the three, and tesamorelin vs cjc-1295 no dac, where half-life is the main difference.
Fat-loss-focused users also look at aod-9604 vs cjc-1295 ipamorelin, which compares a growth hormone fragment to a GHRH and GHRP combination. These are different mechanisms, and none of them is FDA-approved for general weight loss.
Bottom Line
- Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has far more human data than CJC-1295.
- CJC-1295 is not FDA-approved for any human use and has minimal clinical evidence behind it.
- Neither peptide is a proven muscle-building agent in healthy adults.
- Both raise IGF-1 and share similar side effect profiles, so medical supervision matters.
Frequently Asked Questions
Is tesamorelin the same as CJC-1295?
No. Both are GHRH analogs, but they are different molecules with different half-lives and regulatory status. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while CJC-1295 is not approved for human use in the United States.
Which is better for fat loss, tesamorelin or CJC-1295?
Tesamorelin has the stronger evidence, because its clinical trials measured visceral abdominal fat reductions in people with HIV-associated lipodystrophy. CJC-1295 has no comparable body-composition trials, so there is no reliable way to rank it against tesamorelin for fat loss.
Can you buy CJC-1295 legally in the US?
CJC-1295 is not FDA-approved for human use, so it cannot be sold as a prescription drug or a dietary supplement. Products labeled CJC-1295 are typically marketed as research chemicals, which are not held to the same purity and safety standards as approved medications.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.